Bath & Body Works (BBWI)

Bath & Body Works is a specialty retailer of home fragrance, body care, soaps and sanitizer products. At a time when brick-and-mortar retailers face intense competition from online giants like Amazon, Bath & Body Works keeps growing at an impressive rate.

In the most recent quarter, net sales rose 11% year over year to $3.03 billion. Adjusted earnings per share from continuing operations increased 17% year over year to $2.30.

Earlier this year, Goldman Sachs added Bath & Body Works to its Americas Conviction List.

“We believe there is upside potential to current consensus estimates given the expected rollout of the company’s loyalty program to the entire chain in mid-2022,” writes analyst Kate McShane.

Goldman has set a price target of $85 for Bath & Body Works — roughly 70% above where the stock sits today.

Fine wine is a sweet comfort in any situation — and now it can make your investment portfolio a little more comfortable, too. Now a platform called Vinovest helps everyday buyers invest in fine wines — no sommelier certification required.

Invest Now

Salesforce (CRM)

Salesforce is a cloud-based software giant. More than 150,000 companies use its customer relationship management platform to scale their business.

Cloud computing is a booming industry, and Salesforce’s numbers completely reflect that.

In the company’s most recent quarter, revenue surged 26% year over year to $7.3 billion. Management also issued upbeat guidance: It now expects full-year 2023 revenue of $32 billion, marking a year-over-year increase of 21%.

But the stock is down more than 20% in 2022, giving contrarian traders something to think about.

Last month, Goldman Sachs reiterated a ‘buy’ rating on Salesforce and raised its price target on the shares to $360, implying potential upside of more than 80%.

Penn National Gaming (PENN)

Penn National Gaming is a casino and racetrack operator with 44 properties in 20 states and provides online sports betting in 13 jurisdictions.

The shares rallied nicely in pandemic-struck 2020, but have slumped ever since on concerns over slowing growth. They’re down more than 60% over the past year. That could give bargain hunters an opportunity, especially considering how much the company’s business has improved.

In Q4, revenue grew 53% year over year to $1.57 billion, while net income spiked 253% to $44.8 million. The company generated record free cash flow in 2021 and is returning cash to investors. In February, the board approved a $750 million share repurchase program.

Goldman has a ‘buy’ rating on Penn and a price target of $77. With the stock trading at around $38 right now, that target suggests potential upside of 103%.

Fine wine is a sweet comfort in any situation — and now it can make your investment portfolio a little more comfortable, too. Now a platform called Vinovest helps everyday buyers invest in fine wines — no sommelier certification required.

Invest Now

More from MoneyWise

Get a piece of commercial real estate

Enhance your portfolio with high-return commercial real estate

First National Realty Partners is the #1 option for accredited investors seeking superior risk-adjusted returns in the grocery-anchored necessity-based retail space.

While commercial real estate has always been reserved for a few elite investors, outperforming the S&P 500 over a 25-year period, First National Realty Partners allows you to access institutional-quality commercial real estate investments — without the leg work of finding deals yourself.

Invest with First National Realty Partners now.

What to Read Next

Disclaimer

The content provided on MoneyWise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.